Endocrine Abstracts

Background: There are increasing number of reports on immune checkpoint inhibitors induced adverse events including hypophysitis. Hypophysitis tends to occur more with CytotoxicT-lymphocyte-associated protein 4 inhibitors (12-15% of cases) which is a different entity compared to those associated to anti-program death 1 (anti-PD1) inhibitors.Aim: We describe a case of pembrolizumab-associated hypophysitis and conduct a discussion based on a systematic rev...